KA
BMRN icon

Klingman & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Klingman & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-172
Closed -$24K – 420
2015
Q2 		$24K Buy
+172
New +$21.3K 0.01% 238

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Klingman & Associates's BMRN Position: Q3 2015 in Review

Klingman & Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 172 shares — an estimated $24K sold.

Klingman & Associates first reported a position in BMRN in Q2 2015 and held it in 1 quarter. The position peaked at $24K in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

  • Klingman & Associates reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Klingman & Associates sold 172 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $24K.
  • Klingman & Associates first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Klingman & Associates's BioMarin Pharmaceuticals position peaked at $24K in Q2 2015.
  • 393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Klingman & Associates's 13F filing for Q3 2015, filed 9 Feb 2016.